Soham Sankaran’s résumé reads like three different careers stapled together: a Yale computer-science degree, a Cornell robotics PhD he walked away from, and a YC-backed robotics software startup he shut down during COVID. Then came the strangest pivot of all — he taught himself immunology and molecular biology from scratch and founded PopVax, a Hyderabad biotech building RNA vaccines end-to-end. In August 2026, the company’s first candidate — a broadly-protective COVID vaccine called PVX-001 — was dosed in its first human volunteers. PopVax plans to make it open-source. Another Indian health-tech moonshot with honest caveats: NIRAMAI’s Thermalytix.
From robots to ribosomes
Sankaran founded the robotics software company Pashi, backed by Y Combinator, before shutting it as the pandemic scrambled priorities. With a vaccine-skeptical household in his own background — his parents lean toward homeopathy, by his own telling — he spent the COVID years self-studying biology and immunology, going deep enough to start asking why vaccine development still moved so slowly. PopVax was founded in late 2021 and incubated at CSIR-CCMB in Hyderabad; it now employs around 70 people.
The premise is vertical integration. Most biotech startups outsource manufacturing; PopVax built its own integrated RNA Foundry in Hyderabad covering R&D and GMP-capable clinical dose production, so it can design, develop and manufacture its RNA medicines under one roof. The company’s stated mission — the “Million Lives Mission” — is to develop novel vaccines and therapeutics over a decade with the cumulative ability to save a million lives a year. That is an aspiration, not a result.
A full-stack RNA platform — as the company describes it
PopVax describes its platform as spanning generative-AI protein design, high-throughput wet-lab screening, a novel mRNA architecture encoding virus-like particles, a library of novel ionisable lipids for delivery, and fridge-stable (4°C) formulations. All of that is the company’s account of its own technology; none of it has been validated in humans yet. The pipeline the company lists is ambitious: hepatitis C, Strep A, adult pulmonary TB, COVID, flu, malaria, HPV, plus cancer immunotherapies for liver and pancreatic cancers.
Clinical — with the caveats stated plainly
On 31 August 2026, PVX-001 entered a Phase I trial in Melbourne, Australia, with the first two participants dosed — a milestone the company announced itself on its official channel, alongside a commitment to open-source the vaccine after the trial. Here is the critical context: Phase I trials test safety, not efficacy. Nothing PopVax has built has human efficacy data of any kind, and the blog will not imply otherwise. Early animal data discussed in interviews — including a widely quoted flu-vaccine figure — is preclinical mouse work, not peer-reviewed evidence, and is best left out of any serious assessment.
Funding comes from an unusual coalition for an Indian biotech: the Gates Foundation, Vitalik Buterin’s Balvi Fund, BARDA, Renaissance Philanthropy and Good Ventures, per the company’s own job postings and funding coverage. It is the kind of backer list that buys a startup time — and time is what platform biotech needs most — patient capital backing deep tech, the way Pranos Fusion’s tokamak bid is funded.
He dropped out of a Cornell robotics PhD, taught himself immunology, and built a vaccine foundry — now his first RNA vaccine is in human trials.
Key takeaway
PopVax is a bet that the scarcest input in biotech isn’t capital but integration — one team owning the molecule from AI-designed sequence to GMP vial. Whether the science holds will be decided in trials, starting with safety. The honest version of this story is exciting enough without embellishment.
Who founded PopVax?
Soham Sankaran — a Yale computer-science graduate and Cornell robotics PhD dropout who previously founded the YC-backed robotics software company Pashi. He taught himself immunology and biology before founding PopVax in Hyderabad in late 2021.
What is PVX-001?
PVX-001 is PopVax’s broadly-protective COVID vaccine candidate. It entered a Phase I trial in Melbourne, Australia on 31 August 2026, with the first two participants dosed. The company plans to make it open-source after the trial.
Has PopVax proven its vaccines work?
No. Phase I trials test safety, not efficacy. Nothing in PopVax’s pipeline has human efficacy data, and early animal results discussed in interviews are preclinical — they do not show the vaccines work in people.
What is the RNA Foundry?
PopVax’s integrated facility in Hyderabad covering R&D and GMP-capable clinical dose production, per the company — designed so it can design, develop and manufacture its RNA medicines end-to-end rather than outsourcing production.
More Read
Sources & further reading
- PopVax — official site — Company site: platform, Million Lives Mission, RNA Foundry
- PopVax “goes clinical” — official YouTube — Phase I trial announcement, Aug 2026
- Viestories: PopVax funding coverage — Funding history including Gates Foundation grant
